# A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Study · id `cardio:ct-nct01760460` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01760460](<https://clinicaltrials.gov/study/NCT01760460>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01760460

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

## Technical summary

Registry record NCT01760460. Randomized; double masking; primary purpose treatment. Start 2013-03-14 (actual); primary completion 2015-03-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 307 participants (enrolled count; ClinicalTrials.gov record NCT01760460, source copy `cardio:ctgov-nct01760460-2017-06-01`, retrieved 2026-10-31)
- Started: 2013-03-14 (actual) (ClinicalTrials.gov record NCT01760460, source copy `cardio:ctgov-nct01760460-2017-06-01`, retrieved 2026-10-31)
- Primary completion: 2015-03-04 (actual) (ClinicalTrials.gov record NCT01760460, source copy `cardio:ctgov-nct01760460-2017-06-01`, retrieved 2026-10-31)
- Completion: 2015-03-04 (actual) (ClinicalTrials.gov record NCT01760460, source copy `cardio:ctgov-nct01760460-2017-06-01`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01760460-2017-06-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
- Condition: Dyslipidemia
- Intervention (Drug): Anacetrapib
- Intervention (Drug): Placebo for anacetrapib
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia (`cardio:pubmed-28478132`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 95a3e50a4c4f770b258cd6d43366a4f3171a32b613a9acee3040ebb35a047653
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
